Stifel lowered the firm’s price target on Bausch + Lomb (BLCO) to $15 from $17 and keeps a Hold rating on the shares. Following last week’s intraocular lense recall, the firm surveyed 54 ophthalmologists to assess the impact on B+L and broader market implications, telling investors that the survey findings were “less negative than anticipated” as a greater-than-expected proportion of doctors plan to resume using the recalled IOLs once available.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Faces Growth Challenges Amid enVista Lens Recall and Increased Competition
- Bausch + Lomb cut to Equal Weight at Wells Fargo following enVista recall
- Bausch + Lomb downgraded to Equal Weight from Overweight at Wells Fargo
- Bausch + Lomb price reaction to recall ‘likely overdone,’ says RBC Capital
- BofA sees Bausch + Lomb IOL recall news as positive for RxSight